\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationHybrid
This showcase event is organised by HADEA in collaboration with the Joint Action on increasing Capacity building for National Focal Points (JA NFP4Health), the Horizon Europe Partnership for Transforming Health Care Systems (THCS) the Joint Action on cardiovascular diseases (CVDs) and diabetes (JACARDI) and the Horizon Europe Health National Contact Points (HNN3.0)
The event will focus on synergies by implementation, fostered by the clustering activities promoted by HaDEA. Moreover, the event will also harvest the main lessons learned coming from synergies by design, promoted at call level by the EU funding programmes managed by the Agency.
Within the overarching theme of integrated care, the presentations and discussions will be centred around the prevention of cardiovascular diseases and diabetes as well as the promotion of mental health.
More information and registration on the HNN3.0 website. This 2-day event will be held in Rome and there will be also the possibility to participate online. Deadline for registration is 25/09/24.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
